Bellerophon Therapeutics is a
clinical-stage biotherapeutics company.
We are focused on developing innovative products combining novel drugs and devices in the treatment of cardiopulmonary diseases. Our mission is to develop well-studied molecules deployed through innovative delivery systems to treat diseases with significant unmet clinical need.
Bellerophon profiled in the 2016 Winter/Spring edition of MicroCap Review
Click on the link to see the article 2016 MicroCap Review
Bellerophon announces positive data from the recent interim analysis of the phase 2, long-term extension trial of INOpulse for the treatment of Pulmonary Arterial Hypertension (PAH)
To view the press release, interim analysis presentation and webcast, click here
Click here to view Stock News Now interview with Bellerophon’s Chairman and CEO, Jonathan Peacock
Our lead investigational cardiopulmonary product candidate, INOpulse is a combination drug-device therapy that we are developing for the treatment of pulmonary arterial hypertension (PAH), pulmonary hypertension associated with chronic obstructive pulmonary disease (PH-COPD), and pulmonary hypertension associated with idiopathic pulmonary fibrosis (PH-IPF).
Bioabsorbable Cardiac Matrix (BCM) is an investigational medical device deployed via intracoronary injection, which we are developing for the reduction or prevention of ventricular remodeling after an acute myocardial infarction, commonly known as a heart attack.